Neuland Laboratories Limited (BOM:524558)
India · Delayed Price · Currency is INR 12,960
-219 (-1.66%)
At close: Feb 12, 2026
Neuland Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 15,751 | 14,768 | 15,586 | 11,912 | 9,511 | 9,369 |
Other Revenue | - | - | - | 2.88 | 5.99 | 0.56 |
| 15,751 | 14,768 | 15,586 | 11,915 | 9,517 | 9,370 | |
Revenue Growth (YoY) | 2.71% | -5.24% | 30.81% | 25.20% | 1.57% | 22.64% |
Cost of Revenue | 7,981 | 7,505 | 7,338 | 6,138 | 5,535 | 5,547 |
Gross Profit | 7,770 | 7,263 | 8,248 | 5,777 | 3,982 | 3,823 |
Selling, General & Admin | 3,105 | 2,734 | 2,580 | 2,026 | 1,832 | 1,505 |
Other Operating Expenses | 1,410 | 1,224 | 1,038 | 917.43 | 698.58 | 824.83 |
Operating Expenses | 5,350 | 4,613 | 4,214 | 3,471 | 3,021 | 2,726 |
Operating Income | 2,420 | 2,650 | 4,033 | 2,306 | 960.9 | 1,096 |
Interest Expense | -165.81 | -57.89 | -110.74 | -104.02 | -95.34 | -128.01 |
Interest & Investment Income | 105.84 | 105.84 | 82.27 | 15.56 | 9.95 | 16.68 |
Currency Exchange Gain (Loss) | 5.96 | 5.96 | -0.55 | -103.33 | -1.02 | -21.67 |
Other Non Operating Income (Expenses) | 21.55 | -25.08 | -29.23 | -21.45 | -34.79 | -38.19 |
EBT Excluding Unusual Items | 2,388 | 2,679 | 3,975 | 2,092 | 839.71 | 925.14 |
Gain (Loss) on Sale of Investments | 76.83 | 76.83 | - | - | - | - |
Gain (Loss) on Sale of Assets | -73.11 | -73.11 | -4.02 | -8.71 | -18.08 | 128.19 |
Other Unusual Items | 15.54 | 779.58 | 40.36 | 37.85 | - | - |
Pretax Income | 2,408 | 3,463 | 4,014 | 2,157 | 821.63 | 1,053 |
Income Tax Expense | 616.5 | 862.21 | 1,014 | 522.29 | 183.41 | 247.03 |
Earnings From Continuing Operations | 1,791 | 2,601 | 3,001 | 1,635 | 638.22 | 806.31 |
Net Income | 1,791 | 2,601 | 3,001 | 1,635 | 638.22 | 806.31 |
Net Income to Common | 1,791 | 2,601 | 3,001 | 1,635 | 638.22 | 806.31 |
Net Income Growth | -40.26% | -13.32% | 83.52% | 156.21% | -20.85% | 397.40% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Change (YoY) | -0.00% | - | - | - | - | - |
EPS (Basic) | 139.62 | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 |
EPS (Diluted) | 139.62 | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 |
EPS Growth | -40.26% | -13.32% | 83.52% | 156.23% | -20.85% | 397.59% |
Free Cash Flow | - | 1,109 | 1,175 | 1,711 | -372.97 | 839.65 |
Free Cash Flow Per Share | - | 86.45 | 91.59 | 133.35 | -29.07 | 65.44 |
Dividend Per Share | - | 12.000 | 14.000 | 10.000 | 5.000 | 5.000 |
Dividend Growth | - | -14.29% | 40.00% | 100.00% | - | 150.00% |
Gross Margin | 49.33% | 49.18% | 52.92% | 48.49% | 41.84% | 40.80% |
Operating Margin | 15.37% | 17.95% | 25.88% | 19.35% | 10.10% | 11.70% |
Profit Margin | 11.37% | 17.61% | 19.25% | 13.72% | 6.71% | 8.61% |
Free Cash Flow Margin | - | 7.51% | 7.54% | 14.36% | -3.92% | 8.96% |
EBITDA | 3,042 | 3,243 | 4,588 | 2,792 | 1,404 | 1,449 |
EBITDA Margin | 19.31% | 21.96% | 29.44% | 23.43% | 14.75% | 15.47% |
D&A For EBITDA | 622.14 | 593.07 | 554.31 | 486.2 | 443.13 | 352.88 |
EBIT | 2,420 | 2,650 | 4,033 | 2,306 | 960.9 | 1,096 |
EBIT Margin | 15.37% | 17.95% | 25.88% | 19.35% | 10.10% | 11.70% |
Effective Tax Rate | 25.60% | 24.90% | 25.25% | 24.21% | 22.32% | 23.45% |
Revenue as Reported | 16,003 | 14,973 | 15,711 | 12,009 | 9,532 | 9,530 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.